Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/02/2874019/0/en/Chemomab-Therapeutics-to-Present-at-2024-Aegis-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/04/24/2868467/0/en/Chemomab-Therapeutics-to-Report-First-Quarter-2024-Financial-Results-and-Provide-a-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/18/2865252/0/en/Chemomab-Reports-New-Peer-Reviewed-Publication-Reinforcing-the-Clinical-Association-of-Its-CCL24-Target-with-Disease-Severity-and-Mortality-in-Patients-with-Systemic-Sclerosis.html
https://www.prnewswire.com/news-releases/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2023-financial-results-and-provides-a-corporate-update-302082436.html
https://www.prnewswire.com/news-releases/chemomab-awarded-new-patents-for-cm-101-its-first-in-class-monoclonal-antibody-in-clinical-development-for-fibro-inflammatory-diseases-302065634.html
https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-a-business-update-302061454.html
https://www.prnewswire.com/news-releases/chemomab-announces-completion-of-patient-enrollment-in-cm-101-phase-2-primary-sclerosing-cholangitis-trial-and-moves-up-expected-topline-readout-to-midyear-2024-302025023.html
https://investors.chemomab.com/2023-11-16-Chemomab-Presentation-at-ACR-Convergence-2023-Provides-Further-Support-for-Key-Role-of-Its-CCL24-Target-in-the-Pathogenesis-of-Systemic-Sclerosis
https://investors.chemomab.com/2023-11-15-Chemomab-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CM-101-for-the-Treatment-of-Primary-Sclerosing-Cholangitis
https://investors.chemomab.com/2023-11-13-Chemomab-Presents-New-Clinical-Data-Supporting-CM-101s-Anti-Fibrotic-Anti-Inflammatory-Activity-in-Patients-with-Liver-Fibrosis-and-New-Data-Highlighting-Unique-Association-of-Its-CCL24-Target-with-Key-PSC-Pathways-at-AASLDs-The-Liver-Meeting-R